Vickers Vantage Corp. I
VCKA
NASDAQ Capital Market9.01
USD
-0.99
- -
CIK
0001820190
ISIN
KYG9440B1077
Return %
Stock
S&P500
1Y
-10.97
18.21
3Y
-8.53
64.38
5Y
-8.53
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Chien-Chuen Chi
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- Keppel Bay Tower Singapore Singapore 098632
- IPO Date
- Mar 3, 2021
- CIK
- 0001820190
- Website
- vickersvantage.com
- Similar Companies
- Business
- Vickers Vantage Corp. I (NASDAQ:VCKA) operates as a blank check company, or special purpose acquisition company (SPAC), whose primary business is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses; it generates revenue primarily through management fees typically amounting to 2% of gross assets, success fees structured as a percentage of completed merger or acquisition values and post-merger performance incentives. The company targets opportunities principally in technology, healthcare, fintech, renewable energy and income-producing assets such as real estate and energy infrastructure, primarily in the United States with additional focus on emerging markets; it does not currently have operational products or services beyond its SPAC structure but pursues targets with innovative technologies, strong growth potential and robust financial performance. Founded in 2020 and headquartered at 1 Harbourfront Avenue, #16-06 Keppel Bay Tower, Singapore 098632, Vickers Vantage Corp. I completed its initial public offering in April 2021 raising approximately $300 million at $10 per share on Nasdaq; in a major strategic shift, it completed a reverse merger business combination with Scilex Holding Company in November 2022 valued at a pro forma equity of about $1.64 billion, enabling Scilex—a developer and commercializer of non-opioid pain management products—to become publicly traded under a new ticker while providing up to $140 million in gross proceeds for commercialization and clinical development prior to closing.